Home   /   Pressrelease    /   

First Liver transplant with ST...

First Liver transplant with STEEN Solution™ performed

The first clinical liver transplant with a liver perfused with STEEN Solution™ was performed in Toronto, Canada. In total three successful liver transplants have been performed  as part of a phase 1 clinical trial at Toronto General Hospital (TGH)/University Health Network.

In total three successful liver transplants were performed during the summer in Toronto, Canada. The liver was perfused with STEEN Solution™ under normothermic conditions. STEEN Solution™ was originally developed for warm perfusion and evaluation of lungs and is modified when perfusing a liver. The modified STEEN Solution™ decreases inflammation and protects the liver from injury.

“This technique will change the landscape of organ donation by improving organ preservation, allowing us to assess or ‘test drive’ the liver on the device before we transplant it into a patient. We will know how healthy that organ is before the transplant operation,” says Dr. Markus Selzner, a transplant surgeon in the Multi-Organ Transplant Program at TGH, co-investigator of the clinical trial and the transplant surgeon who performed the donor operation. After the Phase 1 safety trial they will move into subsequent phases examining efficacy.

XVIVO Perfusion’s product STEEN Solution™ (together with the XPS™) is the only FDA approved device for evaluating an organ and is currently approved in the USA for evaluation of marginal lungs prior to lung transplantation.

“With STEEN Solution™ having a proven clinical use in lungs, XVIVO perfusion is determined to investigate the clinical use of STEEN Solution™ in other organs as well as other areas of use such as cancer treatment. It is encouraging that the STEEN Solution™ liver study has started,” says Magnus Nilsson, CEO XVIVO Perfusion. 

August 6, 2015
XVIVO Perfusion AB (publ)

Fill out the form to watch the video